Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/GSK Unveiling HIV Joint Venture As ViiV Healthcare

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer and GlaxoSmithKline on Nov. 3 will formally unveil their much-ballyhooed HIV joint venture, announced last April.

You may also be interested in...



GSK Reviews Options For European Business, Adopts New Manufacturing Processes

GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel